Edition:
United Kingdom

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

12.48EUR
23 Apr 2018
Change (% chg)

€-0.07 (-0.56%)
Prev Close
€12.55
Open
€12.57
Day's High
€12.57
Day's Low
€12.35
Volume
43,990
Avg. Vol
78,711
52-wk High
€22.50
52-wk Low
€11.25

Chart for

About

Nanobiotix SA is a France-based oncology focused nanomedicine company. It is engaged in developing nanoparticle technology. It develops new tools for cancer which utilize a physical mode of action at the cellular level of the cancer cell. This disruptive approach may reshape future treatment opportunities. The Company's NanoXray... (more)

Overall

Beta: 1.65
Market Cap(Mil.): €247.56
Shares Outstanding(Mil.): 19.63
Dividend: --
Yield (%): --

Financials

  NANOB.PA Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -1.50 -- --
ROI: -74.41 -0.74 13.19
ROE: -85.27 -2.80 15.00

BRIEF-Nanobiotix FY Net Loss Widens to ‍​26.1 Million Euros

* TOTAL REVENUE IN 2017 AMOUNTS TO EUR 3.7M VERSUS. EUR 5.4M IN 2016

30 Mar 2018

BRIEF-Nanobiotix Presents Data From Phase I/II Liver Cancers Trial Of NBTXR3

* NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIVER CANCERS TRIAL OF NBTXR3 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY GASTROINTESTINAL ANNUAL MEETING

22 Jan 2018

BRIEF-Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers

* NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS

11 Jan 2018

BRIEF-Nanobiotix: FDA Approves First Immuno-Oncology Trial

* NANOBIOTIX : FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL

26 Dec 2017

BRIEF-Nanobiotix Q3 revenue down at 33.0‍​ million euros

* Q3 REVENUE EUR 33.0‍​ MILLION VERSUS EUR 58.6 MILLION YEAR AGO Source text: http://bit.ly/2zKWYHz Further company coverage: (Gdynia Newsroom)

15 Nov 2017

BRIEF-Nanobiotix completes new share issue for about 27.2 million euros

* NANOBIOTIX SUCCESSFULLY COMPLETES APPROXIMATELY EUR 27.2 MILLION PLACEMENT OF NEW SHARES

31 Oct 2017

Earnings vs. Estimates